Facebook
Twitter
LinkedIn
ForwardIntroduction to Theranostics for the Community Radiation Oncologist (PRO 10)
There has been a recent and rapid expansion in the indications for radiopharmaceuticals. This has led to an increase in demand and need for providers who feel comfortable in delivering these therapies especially in the community setting. This activity is geared toward community radiation oncologists who are interested in expanding their scope of practice into radiopharmaceuticals especially for prostate cancer. The activity includes an academic radiation oncologist who will review the current data and indications for radiopharmaceuticals as well as potential future direction. She is followed by two community radiation oncologists who are actively delivering these therapies. One will focus on the regulatory requirements, staffing needs and integration into a radiation oncology clinic. The last speaker discusses how to develop a theranostic clinic in a community setting with discussion of imaging and sustainable business model.
Target Audience
This activity is designed to meet the interests of radiation oncologists.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Identify indications for radiopharmaceuticals for prostate cancer.
- Identify resources needed to implement radiopharmaceuticals in a community clinic.
- Arshin Sheybani, MD, is employed by Iowa-Wide Oncology Research Coalition NCORP.
- Jeff Michael Michalski, MD, FASTRO, MBA, is employed by Washington University School of Medicine.
- Youssef Charara, PhD, is employed by Virginia Cancer Specialists.
- Brandon Robert Mancini, MD, MBA, is employed by BAMF Health.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Meeting Steering Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.